Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Trillium Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Trillium Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Trillium Therapeutics. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Trillium Therapeutics's earnings available for a low price, and how does
this compare to other companies in the same industry?
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Trillium Therapeutics's regulatory filings and announcements.
Trillium Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Trillium Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Trillium Therapeutics's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
A company's financial position is much like your own financial position,
it includes everything you own
The boxes below represent the relative size of what makes up
Trillium Therapeutics's finances.
The net worth of a company is the difference between its assets and liabilities.
Trillium Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Trillium Therapeutics's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of
Trillium Therapeutics's finances. If any of them are yellow this
indicates they may be out of proportion and red means they relate to one of the
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
Low level of unsold assets.
Debt is covered by short term assets, assets are 495.2x debt.
Nearly all companies have debt. Debt in itself isn’t
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.
The graphic below shows equity (available funds) and debt, we ideally want to
see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and
whether the level has increased over the past 5 years.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Bjorn Johan Niclas Stiernholm, Ph.D. has been the Chief Executive Officer since 2002 and President of Trillium Therapeutics Inc., since April 9, 2013. Dr. Stiernholm serves as Director at Trillium Therapeutics Inc. since July 18, 2011. He served as the Chief Executive Officer of Trillium Therapeutics Inc. (TTI ) since 2002 and served as its President. Dr. Stiernholm oversees strategic direction, business development and advancement of scientific programs. Mr. Stiernholm also sits on the board of Vasomune Therap eut ics Inc. He served as Executive Vice President and Chief Scientific Officer of YM BioSciences Inc. until December 2002 and played a key role in the success of YM's 2002 IPO. He led the in-licensing efforts and built a broad pipeline of clinical oncology products at YM BioSciences Inc. He started his career as a member of Allelix Biopharmaceuticals' business development office. He served as an Executive Director at Trillium Therapeutics Inc., sinceJuly 18, 2011. He has been a Director for Stem Cell Therapeutics Corp. since July 18, 2011. He serves as Director of AIM Therapeutics, Inc. He serves as a Director of Ontario Genomics Institute. and Formation Biologics Inc. (formerly AvidBiologics Inc.). Dr. Stiernholm has been a Member of Clinical Advisory Board at YM BioSciences Inc. since December 2002. Dr. Stiernholm received his undergraduate degree from Elon University (North Carolina) and his PhD in Immunology from the University of Toronto, where he also conducted postdoctoral studies.
Bjorn Johan's compensation has been consistent with company performance over the past year.
Bjorn Johan's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Trillium Therapeutics management team is about average.
Bjorn Johan Stiernholm
Chief Financial Officer
Chief Scientific Officer
Chief Development Officer
Chief Medical Officer
Head of Calgary Site
Senior Vice President of Discovery Research
Senior Vice President of Commercial & Business Development
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Trillium Therapeutics board of directors is about average.
Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; and TTI-2341, an epidermal growth factor receptor antagonist, which is in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.